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Abstract: In the last two decades rectal cancer has changed from a surgically managed 
disease into a multidisciplinary treatment model resulting in considerable improvements in 
the survival and outcome. This has been made possible by better understanding of the tumor 
biology and oncogenesis, advances in diagnostic and staging investigations, and the changing 
concepts in surgical excision; from the days of abdominoperineal resection to the concept of 
“zone of upward spread” and low anterior resection to the era of total mesorectal excision and 
transanal excision. Efforts are on the way to risk stratification and identification of predictors 
of nonoperative management. Impressive advances in the adjuvant therapies have seen a sea 
change in the form of postoperative radiotherapy to preoperative radiotherapy to preoperative 
chemoradiotherapy and postoperative adjuvant chemotherapy. This multidisciplinary approach 
is the key to impressive local control rates, decreased metastatic rates, overall survival, and 
enhancement in quality of life. Newer ideas in the understanding of genetic differences in rectal 
cancers have stemmed from the observation that these cancers differ in their response to the 
adjuvant treatment. The present day research has focused these areas of biologic differences 
in cancers and aims to target the specific loci in malignant cells with monoclonal antibodies 
directed against various growth factors, key enzyme inhibition, and genetic manipulation. The 
future research lies in the study of gene expression, micro-array techniques, molecular markers, 
and better understanding of the predictors of tumor response to therapy.
Keywords: carcinoma of the rectum, recent advances, neoadjuvant therapy, total mesorectal 
excision, chemoradiation
Introduction
In the last 25 years rectal cancer has changed from a surgically managed disease into 
a multidisciplinary treatment model resulting in considerable improvements in the 
survival and outcome of rectal carcinoma patients. Surgical resection represents the 
focal point of the multidisciplinary management. Surgery for rectal cancer has ranged 
from abdominoperineal resection (APR) in first described by Czerny in 1884 to the 
concept of “zone of upward spread” described by Miles in 1908.1 Miles emphasized 
the importance of performing a wide perineal excision, including removal of the pelvic 
contents of the rectum, the abdominal attachments of the rectum with a high arterial 
ligation, and the iliac lymph nodes. However it was William Heald who popularized 
the total mesorectal excision and revolutionized the surgical treatment of rectal cancer.2 
This surgical approach to rectal cancer appreciates the subtle fascial planes along with 
the lymphatic and neural anatomy of the pelvis. He described a “zone of downward 
spread” within the mesorectum that requires adequate excision in order to reduce local Clinical and Experimental Gastroenterology 2009:2 50
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recurrence. The relationship between tumor location and 
sphincters and the priority to maintain continence through 
sphincter preservation adds to the challenge of the present day 
surgical management of rectal cancer. The choice of surgical 
approach is dependent upon accurate pretreatment staging 
as well as the role that chemotherapy and radiation play in 
the neoadjuvant and adjuvant settings. The evolution of the 
multidisciplinary management of rectal cancer has resulted 
in impressive local control rates, overall survival rates, and 
enhancements in quality of life. Research continues in the 
laboratory, where significant discoveries and innovations pave 
the way for future progress.
Epidemiology and etiology
Colorectal cancer (CRC) is the most common internal 
malignancy in men and women of western societies and its 
incidence is rapidly increasing in Asia. Colon cancer affects 
men and women almost equally, whilst rectal cancer is more 
common in men (female:male ratio, 1:1.3).3 The average 
lifetime risk for an individual to develop colorectal cancer 
is approximately 6%. This risk increases two- to fourfold 
if the patient has a personal history of or a first-degree 
relative with colorectal cancer. Inflammatory bowel disease 
(IBD) is another risk factor. In the first 10 years after the 
initial diagnosis of ulcerative colitis (UC), the incidence of 
colorectal cancer ranges from 2%–5%; however, this risk 
increases 1% for each year of disease thereafter. For all 
patients with UC, the cumulative risk for colorectal cancer at 
25 years is 25%. Crohn’s colitis is associated with a similar 
risk for colorectal cancer. This is often not appreciated by 
clinicians because patients with severe Crohn’s disease 
often undergo proctocolectomy before their long-term risk 
becomes an issue.
Genetic risk factors also have been implicated in the 
development of colorectal cancer. One is familial adenoma-
tous polyposis (FAP), an autosomal dominant syndrome with 
100% risk of developing colorectal cancer. The abnormality 
is caused by a defect in the APC gene located on chromosome 
5q21. Patients with FAP develop hundreds or thousands of 
adenomas by their twenties, and colorectal cancer develops 
in all patients by age 50 if untreated. A second genetic abnor-
mality associated with the development of colorectal cancer 
is related to defects in the mismatch repair genes MSH2 and 
MLH1. Mismatch repair genes affect the repair of DNA repli-
cation errors and spontaneous base repair loss and contribute 
to hereditary nonpolyposis colorectal cancer (HNPCC). 
Despite the name, these cancers arise from adenomas and 
may account for 5% of all colorectal malignancies.
Dietary fats, especially red-meat fats, have been 
implicated as risk factors for colon and rectal cancer.4 
Populations that consume less than 15% of their diet as fat 
have a lower incidence of colorectal cancer, whereas people 
who take in 20% of their diet as fat, either as unsaturated 
animal fat or as highly saturated vegetable oils, have an 
increased risk of cancer.
Dukes had described “adenoma-to-carcinoma sequence,” 
in 1926, which was further advanced and proven on a genetic 
model by Vogelstein.5 The majority of patients with rectal 
cancer do not have an inherited component; instead, there is 
an initiating genetic mutation, such as of an oncogene like ras, 
that leads to abnormal cell growth. Subsequently, mutations 
resulting in inactivation of tumor suppressor genes, such as 
p53, allow for progression to cancer. The time course for 
polyp development and transformation to cancer is thought 
to be 5–10 years. Most adenomas remain benign; however, 
histologic type, polyp size, and evidence of dysplasia are 
associated with transformation. Approximately 75%–85% 
of adenomas are tubular, 8%–15% are tubulovillous, and 
5%–10% are villous. Villous histology is associated with an 
increased risk of cancer development. About 50% of polyps 
greater than 2 cm in diameter harbor areas of carcinoma, 
whereas only 1% of polyps less than 1 cm in diameter show 
evidence of malignant transformation.
Staging investigations
Accurate staging has a critical role in the decision 
making process of patients with rectal cancer. There is an 
increasing role for imaging in the staging of rectal cancer 
before beginning therapy. The four most commonly used 
imaging modalities include transrectal ultrasound (TRUS), 
computerized tomography (CT), magnetic resonance imaging 
(MRI), and positron emission tomography (PET). The 
information offered by these imaging modalities, necessary 
to select appropriate treatment, include depth of tumor and 
adjacent organs invasion (T stage), lymph node involvement 
(N stage), and metastatic spread (M stage).
Transrectal ultrasound
Transrectal ultrasound (TRUS) is the most accurate 
preoperative staging tool for rectal cancer (Table 1). Several 
studies have shown that the overall accuracy for T stage is 
67% to 93% and for N stage is 48% to 61%.6,7 Compared with 
CT scanning, TRUS permits a more accurate characterization 
of the primary tumor and the status of the perirectal lymph 
nodes. Localized cancers involving only the mucosa and 
submucosa usually can be distinguished from tumors that Clinical and Experimental Gastroenterology 2009:2 51
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penetrate the muscularis propria or extend through the rectal 
wall into the perirectal fat.
CT scan of abdomen and pelvis
Abdominal and pelvic CT scans can demonstrate regional 
tumor extension, lymphatic and distant metastases, and 
tumor-related complications such as perforation or fistula 
formation. CT scan has been the part of the standard 
preoperative staging for rectal cancer. Its accuracy in 
determining the depth of invasion is less than that of TRUS 
or endorectal coil MRI (ecMRI). The sensitivity of CT scan 
for detecting distant metastasis is higher (75%–87%) than 
for detecting perirectal nodal involvement (45%–73%) or the 
depth of transmural invasion (70%–82%).7 Metastatic lymph 
nodes are hypodense, round and more than 1 cm in size.
Mri
Both ecMRI and surface coil MRI are becoming more useful 
in the pretreatment evaluation of patients with rectal cancer. 
The ecMRI offers some advantages compared with TRUS. 
It permits a larger field of view, it may be less operator- and 
technique-dependent, and it allows study of stenotic tumors.8 
Like TRUS, ecMRI can discriminate small-volume nodal 
disease and subtle transmural invasion, identify involved 
perirectal nodes on the basis of characteristics other than size, 
with accuracy rates of 50%–95%. The ecMRI can identify 
tumor foci not only within the mesorectum but also outside 
the mesorectal fascia. It has 88% accuracy in predicting the 
stage of disease. The specificity and sensitivity of ecMRI 
with combined intravenous and endorectal contrast material 
to predict infiltration of the anal sphincter were 100% and 
90%, respectively. Surface coil MRI may be beneficial 
in predicting tumor-free resection margin by visualizing 
involvement of mesorectal fascia. A recent meta-analysis 
of TRUS, CT, and MRI reported that TRUS and MRI had 
similar sensitivity (94%) in T staging, but TRUS had higher 
specificity (86%) than MRI (69%).9 Of great concern was 
the equally poor sensitivity (67%) and specificity (77%) 
of TRUS and MRI in detecting lymph node metastases. 
CT scan cannot reliably predict T and N stage. TRUS is 
limited by its inability to detect lymph nodes outside the 
range of its transducer (such as iliac, mesenteric, inguinal, 
and retroperitoneal). CT and MRI offer the advantage of 
providing detailed anatomic information, as well as detecting 
abdominal and pelvic metastatic spread.
PET
Metabolic imaging with PET has an evolving role in assessing 
the extent of pathologic response of primary rectal cancer 
to preoperative chemoradiation and may predict long-term 
outcome. Additionally, it has an accuracy of 87% for 
detecting recurrence of rectal cancer after surgical resection 
and full-dose external-beam radiation therapy.10 While PET 
scans are positive in 90% of primary and recurrent tumors 
and in distant metastases, they are relatively inaccurate for 
nodal metastases. Two important functions of PET scans 
are the detection of regional and metastatic disease and the 
assessment of tumor response to therapy. Recently, several 
small series have reported that the PET scan has changed the 
treatment in as many as 17% of patients and has altered the 
preoperative stage in nearly 40% of patients.11 The PET scan 
may be useful in the assessment of tumor response to preop-
erative therapy and preliminary studies indicate that it is more 
accurate in assessing response to therapy than the CT scan.12 
As modern multislice CT scanners can generate images of the 
chest and abdomen in one breath hold, they have become a 
very effective tool for screening distant metastases and with 
a sensitivity varying between 70%–85%, CT is the second 
most sensitive noninvasive diagnostic tool for the detection 
of liver metastases, after contrast-enhanced MRI.13 When 
the functional information of 2-fluoro-2-deoxy-D-glucose 
(FDG)-PET is added to the CT images in hybrid whole 
body PET-CT imaging, the sensitivity for lesion detection is 
further improved.13 Whole body MRI will become a serious 
competitor to PET-CT for distant staging of colorectal cancer 
patients as MRI is less costly than PET-CT and there is no 
exposure to radiation.14
Preoperative bowel preparation
The role of mechanical bowel preparation (MBP) in rectal 
surgeries is still evolving. Since most of the studies involve 
colonic resections and only few studies have focused only on 
rectal resections, the body of evidence is inadequate. Tradi-
tionally, rectal washouts were common and are still in widely 
practiced. However in a in a multicenter randomized trial by 
Table 1 Endoscopic ultrasound staging of rectal tumors
Stage Description
uT1 Invasion confined to the mucosa and submucosa
uT2 Penetration of the muscularis propria but not through  
to the mesorectal fat
uT3 invasion into the perirectal fat
uT4 invasion into the adjacent organ
uN0 No enlargement of lymph nodes
uN1 Perirectal lymph nodes enlargedClinical and Experimental Gastroenterology 2009:2 52
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Contant and colleagues,15 the rate of anastomotic leakage did 
not differ significantly between with and without MBP groups 
(p  0.69). Although other septic complications, fascial 
dehiscence and mortality did not differ, those with MBP had 
fewer abscesses after anastomotic leakage (p  0.001). In a 
study by Bretagnol and colleagues16 in 2007, 51 consecutive 
patients with rectal resection without MBP were compared 
to a matched group of 61 controls with MBP, which showed 
an overall higher morbidity in the MBP group. A similar 
anastomotic leak rate (8% vs 10%; p = 1.000) was observed, 
though peritonitis occurred more in the no-MBP group and 
a trend toward higher infectious complications was noted in 
the MBP group. Another nonrandomized retrospective study 
(n = 144) from the Netherlands, which included low anterior 
resections without MBP reported a less than 5% anastomotic 
leakage rate as compared to a leakage rate of up to 18% in 
studies using MBP.17 Based on the accrued evidence it is too 
premature at present to come to a conclusion whether MBP 
should be omitted in rectal surgeries.18
Conceptual advances in surgical 
resection of rectal cancer
The primary goal of surgical treatment for rectal cancer is 
complete eradication of the primary tumor along with the 
adjacent mesorectal tissue and the superior rectal artery 
pedicle. Although the aim of surgery is to maintain bowel 
continuity, cancer removal should not be compromised in an 
attempt to avoid a permanent colostomy. After establishing 
the diagnosis and completing the staging work-up, a decision 
is made whether to pursue immediate resection or administer 
preoperative chemoradiotherapy depending on the site, fixity 
and operability, histological type, grade and stage including 
intramural extent and lymph node status.
Optimal distal resection margins
For surgically treated rectal cancer, the optimal distal resec-
tion margin remains controversial. Although the first line of 
rectal cancer spread is upward along the lymphatics, tumors 
below the peritoneal reflection can spread distally via intra- 
or extramural lymphatic and vascular routes. The use of 
APR for low rectal cancers traditionally has been based on 
the need for a 5-cm distal margin of normal tissue. Distal 
intramural spread usually is limited to within 2.0 cm of the 
tumor unless the lesion is poorly differentiated or widely 
metastatic. The National Surgical Adjuvant Breast and Bowel 
Project demonstrated no significant differences in survival 
or local recurrence when comparing distal rectal margins of 
less than 2 cm, 2–2.9 cm, and greater than 3 cm.19 Therefore, 
a 2-cm distal margin is acceptable for resection of rectal 
carcinoma. Now with the use of neoadjuvant chemoradiation 
and Frozen section biopsy of resected margins, 1 cm distal 
margin is also acceptable for distal rectal cancer to preserve 
the sphincters.20
Optimal radial resection margins
In the last decade, the importance of obtaining an adequate 
radial margin has been appreciated and stressed upon. Tumor 
involvement of the circumferential margin (CRM) has been 
shown to be an independent predictor of local recurrence, 
distant metastasis, and overall survival.21 In their review 
of more than 17,500 patients, Nagtegaal and Quirke21 
demonstrated that following neoadjuvant therapy (both 
radiotherapy and radiochemotherapy) the predictive value 
of the CRM for local recurrence is significantly higher than 
when no preoperative therapy has been applied. So the radial 
margin is more critical than the proximal or distal margin 
for local control. In one report of 90 patients undergoing 
resection for rectal cancer, the length of mesorectum beyond 
the primary tumor that needs to be removed was thought to 
be between 3 and 5 cm because tumor implants usually are 
seen no further than 4 cm from the distal edge of the tumor 
within the mesorectum.22 Therefore, in proximal rectal 
cancer, mesorectal excision 5 cm below the lower border of 
the tumor should be the goal.
Total mesorectal excision and autonomic 
nerve preservation
Locoregional tumor control in rectal cancer surgery has 
improved significantly over the last 15 years after the 
introduction of total mesorectal excision (TME). The concept 
of total mesorectal excision (TME) proposed by Heald has 
been shown to improve disease free and overall survival.2 In 
1986, Quirke and colleagues proved that pelvic recurrence 
is a direct consequence of inadequate mesorectal excision, 
which leaves regional disease in the pelvis.23 TME is based on 
the fact that the mesorectum is often a site of nodal or occult 
micrometastatic disease that is frequently left in situ within the 
pelvis, when the mesorectum is bluntly mobilized and divided 
during “traditional” surgery. TME involves sharp dissection 
under direct vision in the avascular areolar plane between 
the fascia propria of the rectum, which encompasses the 
mesorectum, and the parietal fascia overlying the pelvic wall 
structures.24 This procedure emphasizes autonomic nerve pres-
ervation. TME in conjunction with an LAR or APR involves 
precise dissection and removal of the entire rectal mesentery, 
including that distal to the tumor, as an intact unit.Clinical and Experimental Gastroenterology 2009:2 53
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A large international retrospective study reported a local 
recurrence rate of 32% to 35% following conventional 
surgery compared with 4% to 9% following TME.25 The 
study also reported a 30% absolute increase in the overall 
survival and cancer-specific survival in the TME group. The 
Dutch ColoRectal Cancer Group noted similar findings when 
they analyzed data from two prospective randomized studies. 
The introduction of TME decreased the local recurrence rate 
from 16% to 9%, and TME was an independent predictor of 
overall survival.26
Extended lymphadenectomy
Analysis of an intergroup trial on rectal cancer has determined 
that the minimum number of lymph nodes examined to define 
node status accurately is 14.27 The issue of high ligation 
of the IMA is with regard to where the vascular pedicle 
is divided. Traditional ligation of the vascular pedicle is 
performed just distal to the origin of the left colic artery. 
However, anatomic studies have revealed that as many as 
10 lymph nodes could be found between the origin of the 
left colic vessel and the origin of the IMA.28 Therefore, high 
ligation of the IMA was proposed as a method to improve 
resection and survival. However, subsequent reports failed 
to support the superiority of high ligation, and it is not 
routinely practiced for oncologic reasons.29 Low rectal car-
cinomas tend to develop lateral node metastasis and it was 
demonstrated previously that lateral node dissection reduce 
the local recurrence rate and survival,30 but at the cost of 
high rates of morbidity in the form of urinary and sexual 
dysfunction.31 Sexual dysfunction is observed in 75%–95% of 
all patients and about 40%–50% patients suffer from urinary 
dysfunction.30 Although the urinary function may improve 
over time, the sexual functional loss has been observed to 
be permanent. Thus in the absence of improved survival, the 
price of such significant morbidity is too high to advocate 
extended lateral lymphadenectomy as a routine procedure. 
Later on Sugihara and colleagues reported the efficacy of 
pelvic autonomic nerve preserving (PANP) while perform-
ing lateral lymph node dissection.32 However, at present 
with the routine use of and advancement in the protocol and 
technique of neoadjuvant and adjuvant therapy, there is no 
role for prophylactic lateral lymph node dissection in the 
treatment of rectal cancer.
Local excision
For selected T1 and T2 lesions without evidence of nodal 
disease, transanal full-thickness excision often provides an 
adequate resection of the primary tumor mass and can spare 
the patient the morbidity of a more extensive rectal resection. 
However, it does not stage the nodal drainage areas and there-
fore cannot provide as complete staging and management of 
the tumor as a definitive resection. After local excision, if the 
pathology is unfavorable, the patient should be counseled to 
have further therapy, including chemoradiation therapy and 
either a low anterior resection or APR with total mesorectal 
excision. Preoperative staging, primarily with TRUS or MRI, 
is the most helpful in identifying appropriate patients for a 
local excision. The present day accepted criteria for tumors 
amenable to local excision includes a T1 or T2 tumor with a 
favorable histology. The tumor should not be fixed or large 
in size (>4 cm), and should not occupy more than 40% of the 
circumference. Local lymph nodal involement should deter 
one from local resection.33
Tumors less than 3 cm from the dentate line but not 
invading the sphincters usually can be resected via a transanal 
procedure. Tumors 5 cm from the dentate line may need a 
transcoccygeal approach or transanal endoscopic microsur-
gery (TEM). Tumors 7–10 cm from the dentate line require 
TEM or should be considered for a low anterior resection.
If pathologic evaluation of the resected specimen 
indicates high grade, positive margins, lymphovascular or 
perineural invasion, a more radical surgery is recommended. 
Local excision for early (T1) rectal cancers is highly attrac-
tive because of its low morbidity, rapid recovery time and 
outstanding long-term functional results. Unfortunately there 
are no randomized trials addressing this question. The largest 
published series of local excision alone for T1 rectal cancer 
reports tumor recurrence rates of 4% to 29% and overall 
survival rates of 83% to 100%.34 The majority of tumor recur-
rences are local. This indicates that inadequate resection of 
loco-regional disease is a major cause of treatment failure. 
Once tumor recurrence has been detected, salvage therapy 
has limited curative potential. Stringency of patient selection 
is undoubtedly important especially in T2 tumors.
Laparoscopic rectal resections
While randomized trials have established laparoscopic 
colectomy as an accepted procedure for colon cancer, only 
limited randomized data are available for patients with rectal 
cancer. The only large randomized trial that has included 
patients with rectal cancer is the English CLASICC trial, 
comparing the conventional versus laparoscopic assisted 
surgery in colorectal cancer.35 The trial showed equivalent 
length of bowel resection, equivalent lymph node harvest, 
and equivalent complication rates. A significant concern is 
the high rate of positive surgical margins among all patients, Clinical and Experimental Gastroenterology 2009:2 54
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and in particular in those patients treated by laparoscopic 
low anterior resection (12%) compared with open low 
anterior resection (6%). The study was unable to document 
a significant postoperative quality of life benefit associated 
with laparoscopic surgery. Laparoscopic resection for rectal 
cancer has technical limitations and a potential for harm. 
Additional randomized trials are needed to document safety, 
efficacy, and benefit to patients.
rectal cancer associated with risk factors
If rectal cancer is associated with ulcerative colitis and 
familial adenomatous polyposis, the total proctocolectomy 
is the surgical recommendation. For HNPCC there is a better 
prognosis with these cancers than when compared with 
age-matched controls with non-HNPCC colorectal cancer. 
Surgical recommendation is the standard resection as in 
other cases of rectal cancer. There is 45% risk of having 
metachronous colon cancer, so total colectomy may be 
justified. The role of panhysterectomy (in women) in same 
sitting is investigational and has some justification as there 
is risk of endometrial and ovarian cancer.
risk of recurrence after resection  
of rectal cancer
After surgical resection, a proportion of those treated will 
relapse, predominantly with distant metastatic disease. 
Fifty to 60% of persons with Stage III and 25% with Stage 
II disease will relapse within 5 years.36 This is due to the 
presence of micrometastatic disease at the time of surgery. 
Such disease can potentially be eradicated with the use of 
adjuvant therapies. The risk of relapse may be estimated by 
assessing the clinical and histologic features of the cancer. 
Poor risk clinical features include higher TNM stage, elevated 
preoperative carcinoembryonic antigen (CEA), insufficient 
lymph node sampling (10 nodes), and presentation with 
colonic perforation or obstruction.37 Metastasis to regional 
lymph nodes is the factor most strongly predictive of out-
come following complete surgical resection. Other factors 
have consistently been implicated as of prognostic value, but 
remain to be validated in prospective trials. These include the 
histological grade of the cancer, lymphovascular invasion, 
residual tumor following neo-adjuvant therapy for rectal 
cancer, and microsatellite instability (MSI).37 There is no 
prospective evidence to suggest these factors aid assessment 
of disease-free and overall survival, or serve as predictive 
factors for adjuvant therapy benefit. Evidence suggests that 
cancers displaying MSI have a better prognosis stage for 
stage compared to microsatellite stable cancers and that 
persons with such cancer may not benefit from adjuvant 
5-FU chemotherapy; however, the literature regarding the 
latter remains conflicting.38,39
Advances in adjuvant 
chemoradiation
Treatment of rectal cancer aims at improvement in local 
control and long-term survival with preservation of anal 
sphincter, bladder, and sexual function while maintaining 
or improving quality of life. A consistent challenge has 
centered not only on these important goals but also on 
the accurate reporting of surgical technique and precise 
pathologic staging. Critical surgical management issues 
include obtaining a total mesorectal excision, autonomic 
nerve and sphincter preservation, circumferential and distal 
resection margin clearance, restoration of bowel continuity, 
and enhancement of postoperative quality of life.40 Since 
1990 postoperative chemoradiation has been the standard of 
care in localized rectal cancers. The concept of preoperative 
neoadjuvant chemoradiation though less than a decade old, 
is a formidable one. The GI Intergroup 0114, a phase III 
postoperative adjuvant chemoradiation trial including 
nearly 1,700 patients with stage II and III rectal cancer, 
which evaluates chemotherapy and chemoradiation with 
bolus 5-FU with or without leucovorin and/or levamisole, 
noted significant survival differences determined by the 
number of lymph nodes resected and examined.41 In patients 
who had 14 or more lymph nodes sampled, survival was 
82%, compared with only 68% in those with 0 to 4 resected 
nodes. This trial also defined two risk groups based on T and 
N staging. Seven-year survival and local recurrence were 
significantly more favorable in patients with low-risk (T1–2N+ 
or T3N0) disease than those with high-risk (T3N+ or T4Nany) 
disease (70% versus 45%, respectively [p  0.0001]; 9% 
versus 18%, respectively [p  0.0001]).
Of note, neither of the two most recent postoperative GI 
Intergroup trials evaluating chemotherapy and chemoradiation 
(INT 0114 and INT 0144) has shown a relapse-free or 
overall survival advantage favoring any 5-FU schedule, 
whether administered as bolus or infusion therapy or admin-
istered with leucovorin and/or levamisole.41,42 However, the 
original work on this topic by O’Connell and colleagues43 
demonstrating a 10% benefit of protracted venous infusion of 
5-FU over the bolus dose in decreasing local tumor relapse 
(47% to 37%; p = 0.01) and distant metastasis (40% to 31%; 
p = 0.03) still remains a valid practice. Both these techniques 
have been accepted for concurrent chemoradiotherapy by 
the National Comprehensive Cancer Network (NCCN) Clinical and Experimental Gastroenterology 2009:2 55
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clinical guidelines (2009) on management of rectal cancer. 
Preoperative chemoradiation in patients with stage II and III 
rectal cancer has clearly emerged as the preferred approach, 
with goals of improving the number of patients obtaining 
a complete response and decreased local recurrence rate, 
increasing both the resectability rate and the ability to 
perform sphincter-sparing surgery, downstaging based 
on clinical T and N status, and reducing the morbidity of 
combined modality therapy. As one example, the German 
Rectal Cancer Group compared neoadjuvant versus 
adjuvant chemotherapy and radiation, showing improved 
local recurrence (6% versus 13%; p = 0.0006) and twice 
the number of sphincter-sparing procedures with the 
neoadjuvant approach; however, five-year disease-free 
and overall survival were comparable.44 NASBP R-03 data 
from the 253 patients suggested no significant trend toward 
improvement at three years favoring preoperative versus 
postoperative therapy (overall survival, 85% versus 78%, 
respectively [p = 0.15]; disease-free survival, 70% versus 
65%, respectively [p = 0.40]; and relapse-free survival, 77% 
versus 70%, respectively [p = 0.22]).45
Since both preoperative and postoperative adjuvant 
strategies were used in the United States, the GI Intergroup 
designed E3201 in 2001 for comparison of two strategies. The 
trial offered a “dealers’ choice,” allowing patients and physi-
cians to select either preoperative chemotherapy and radiation 
or postoperative combined modality therapy. Because both 
irinotecan and oxaliplatin at the time were incorporated in 
adjuvant colon cancer clinical trials, E3201 also planned 
to compare the effectiveness of combination therapy in a 
three-arm design evaluating FOLFOX versus FOLFIRI 
versus 5-FU/LV. Subsequently E3201 was terminated due 
to a growing preference for preoperative chemoradiation and 
an interest in biological treatment combinations. Follow-
up data in 123 patients provided important comparative 
toxicity information, showing that FOLFOX can be safely 
administered to patients with rectal cancer following chemo-
radiation.46
Recent phase I/II neoadjuvant rectal cancer trials have 
focused on the role of combination chemotherapy regimens 
with radiation as an effort to further improve complete 
response before surgical resection. CALGB 89901 evalu-
ated continuous infusion 5-FU, weekly oxaliplatin, and 
radiation in patients with T3 or T4 rectal cancer showing a 
complete pathologic response of 25%.47 Eastern Coopera-
tive Oncology Group designed a phase I oxaliplatin dose 
escalation trial, administering every other week oxaliplatin 
with continuous infusion 5-FU and radiation; the rate of 
microscopic residual disease was found to be 50%, with 
a pathologic complete response of 30%.48 Preoperative 
radiation, oxaliplatin and capecitabine resulted in significant 
downstaging of patients in a European trial.49 In addition, a 
small phase I rectal cancer trial suggested an antivascular 
and antitumor effect with the addition of the monoclonal 
antibody bevacizumab.50
The adverse effect of preoperative radiotherapy remains 
an area of concern in rectal cancer patients as radiation toxicity 
adversely affects the quality of life. Acute toxicity includes 
complications of wound healing especially perineal wound 
healing, gastrointestinal complaints like nausea, vomiting, 
intestinal obstruction, enteritis and proctitis, genitourinary 
and neurological symptoms, while late adverse effects occur 
in the skin, urinary tract, vascular and the skeletal system. The 
magnitude of morbidity has not been thoroughly documented 
as few studies have analyzed the outcome after long-term 
follow up. In a large series, Birgisson and colleagues51 
compared the adverse outcome of preoperative radiotherapy 
followed by surgery to surgery alone and found that irradiated 
patients had higher readmission rates, increased incidence 
of gastrointestinal symptoms like nausea, abdominal pain, 
and importantly, bowel obstruction.
Numerous rectal cancer treatment questions remain 
unanswered. Are there subsets of patients who may not 
require radiation therapy? Gunderson and colleagues52 
have evaluated the effect of T and N stage and treatment on 
survival and relapse of rectal cancer as a pooled analysis. 
The authors observed that patients with intermediate-risk 
rectal cancer (T1,2N1, T3N0) seem to derive no additional 
benefit from radiation in combination with surgery and 
chemotherapy when compared to patients treated with 
surgery and chemotherapy without radiation. In Europe, 
investigators have studied short course radiation sched-
ules, which, in contrast to prolonged course radiation, 
raises questions about the importance of downstaging and 
surgical resectability as well as the effect of pathologic 
complete response on survival.53,54 The second important 
question raises the issue whether in selected patients with 
rectal carcinoma receiving chemoradiotherapy (CRT), 
surgery may be spared. Pathologic complete response 
rate of 25%–30% have been observed in early stage rectal 
tumors after completion of CRT.55,56 This questions the 
role of surgery. In a prospective study by Habr-Gama and 
colleagues,57 the patients with T2–T4 tumors received 
5FU-based CRT preoperatively. After eight weeks, they 
were reassessed and 71 out of 265 patients (26.8%) had 
complete clinical response, and were spared of surgery Clinical and Experimental Gastroenterology 2009:2 56
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and followed up, while the rest were treated with rectal 
resection. The five-year overall survival rates were similar, 
88% in the observed group compared to 92% in the surgery 
group (not significant). In another study by Onaitis and 
colleagues, observation showed no significant advantage in 
local recurrence, disease-free survival and overall survival 
rates between the clinically complete and partial responders 
and pathologically complete and partial responders.58 The 
authors concluded that clinical evaluation following neo-
adjuvant CRT is unreliable as micrometastasis may persist. 
Hence observation policy in these patients should be taken 
with caution. Although in a subset of patient surgery may 
be spared after neoadjuvant CRT, it is unclear at present 
which patients are going to respond completely and thus 
prediction is difficult and not backed by sound evidence. 
Bigger prospective series are required to identify the fac-
tors responsible for clinical and pathological response, 
especially complete response in rectal cancers. It is thus 
believed that the best opportunity to improve survival in 
patients with rectal cancer will require continued focus 
on adjuvant chemoradiotherapy strategies, while at the 
same time pursuing detailed assessment of both acute and 
chronic toxicities. Additionally, if treatment strategies are 
to be successful in patients with rectal cancer, enhanced 
understanding of tumor biology is essential.
Other advances in treatment  
of rectal carcinoma
immobilization molds and tissue 
expanders
A number of investigators have evaluated the effectiveness 
of custom bowel immobilization molds and other devices 
to decrease the amount of small bowel irradiated.59 These 
have generally been partially effective in minimizing bowel 
irradiation, but are dependent on precise location of the device 
relative to the patient. For patients treated postoperatively, 
surgical maneuvers to keep small bowel from being fixed in 
the pelvis can be effective in minimizing bowel irradiation. 
Pelvic tissue expanders have been used to decrease in small 
bowel volume in the radiation field and a decrease in acute 
toxicity. Reperitonealizing the pelvic floor or having a surgical 
flap inserted into the pelvis can also be of substantial use, and 
these are the techniques most commonly used at present. The 
placement of surgical clips in the high-risk areas in the pelvis 
to better define the tumor volume for postoperative irradiation 
can be of enormous benefit to the radiation oncologist in 
limiting the extent of the high-dose region.
Monoclonal antibodies and targeted 
therapy
Though chemotherapeutic agents form the cornerstone of 
adjuvant treatment in rectal cancers, development of mono-
clonal antibodies and rapid incorporation of novel ‘targeted’ 
therapies have taken place in the last decade, supported by 
the results of randomized clinical trials. Among the most 
promising of these agents are agents that inhibit farnesyl 
transferase, vascular endothelial growth factor (VEGF) 
receptor and epidermal growth factor receptor (EGFR), 
and other inhibitors of angiogenesis. Ras oncogenes are 
mutated in more than 40% of colorectal cancers.60 Farnesyl 
transferase facilitates the association of ras through the inner 
surface of plasma membrane. Inhibition of this enzyme 
has shown promising antitumor activity and a number of 
inhibitors of farnesyl transferase have been shown to have 
significant clinical efficacy.61,62 VEGF is another important 
target since it is a promoter of angiogenesis63 and increased 
expression of VEGF is associated with increased metastasis 
and poor prognosis in colorectal cancer.64 Several strategies 
for inhibition of VEGF like VEGF antisense, monoclonal 
antibodies and specific small molecule inhibitors have been 
developed.65 Bevacizumab, the monoclonal antibody target-
ing VEGF, as well as cetuximab and panitumumab, which 
are monoclonal antibodies against EGFR, have recently been 
approved to be used against advanced colorectal cancer. 
Although bevacizumab seems to have no significant clinical 
activity as a single agent in advanced colorectal cancer and 
the activity of single-agent cetuximab is only modest, their 
efficacy improves when combined with chemotherapy.66,67 
Cetuximab has been shown to increase the efficacy of 
irinotecan in irinotecan-refractory patients, indicating that 
cetuximab may make tumors more sensitive to chemo-
therapeutic agents.68 Furthermore, a combined analysis of 
three studies suggests that the addition of bevacizumab may 
even compensate for the lack of an active chemotherapeutic 
agent in the first-line setting because patients treated with 
FU/leucovorin plus bevacizumab had improved results 
when compared with patients administered FU/ leucovorin 
or irinotecan/FU/leucovorin.69 Moreover, novel antibodies 
and tyrosine kinase inhibitors are undergoing active inves-
tigation in clinical trials.70
Dietary supplements and radioprotectors
Randomized trials have examined the efficacy of various 
compounds to decrease bowel toxicity. These trials have 
included such compounds as butyric acid to decrease chronic 
radiation proctitis, sucralfate enemas to decrease acute Clinical and Experimental Gastroenterology 2009:2 57
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radiation proctitis, olsalazine to decrease acute enteritis, 
and mesalazine (5-aminosalicylic acid) to decrease acute 
radiation enteritis.71 All of these trials have been negative. 
A lactose-restricted diet has not been effective in decreasing 
symptoms, and the radioprotector WR-2721 also has not 
shown benefit in some trials but with a suggestion of benefit 
in others.
Molecular predictive markers
With better understanding of the tumor biology and 
molecular phenotype of rectal cancers, several biological 
markers have shown to be useful predictors of outcome 
and/or response to treatment. The availability of a number 
of active agents has helped select a particular drug or a 
drug combination that would have an increased likelihood 
of efficacy or a decreased likelihood of toxicity. Of these 
the most extensively studied are thymidylate synthase (TS) 
and p53. It has been seen that TS activity correlates directly 
with response to 5-FU in advanced disease72 and also as 
predictor of survival and disease-free survival.73 Although 
the prognostic significance of p53 is not clear, an interaction 
between p53 and TS levels has been observed.74 Another 
promising avenue of investigation has been the elucidation of 
markers of resistance to 5-FU-based chemotherapy derived 
from the knowledge of its metabolic pathways. It has been 
observed that high levels of dihydropyrimidine dehydroge-
nase (DPD) or thymidine phosphorylase (TP), as measured 
in a tumor specimen by reverse transcriptase-polymerase 
chain reaction, predict a failure to respond to an infusional 
5-FU regimen.
Allelic loss is widespread in colorectal cancers and 
the clinical significance of allele loss of 17p and 18q 
has been defined in predicting prognosis75,76 along with 
MSI and transforming growth factor β-1 receptor II 
mutation. Patients without 18q loss of heterozygosity 
(LOH) and with MSI positive tumors with transforming 
growth factor β-1 receptor II mutation have the best 
prognosis.77 MSI-positive patients with colorectal cancers 
respond significantly better to adjuvant 5-FU/levamisole 
chemotherapy.78
Gene therapy and gene expression
Colorectal cancer is a reasonable potential target for gene 
therapy approaches because regional administration of 
a gene vector may be practical. Trials of different gene 
therapy approaches, including virus-directed enzyme prodrug 
therapy, immunogenic manipulation, gene correction, and 
viral therapy have all been initiated.79,80
One of the most important advances in rectal cancer 
management has been the development of tumor banks.81 The 
gene signatures from DNA chip analysis (DNA microarray) 
are already in use in predicting the response to adjuvant 
therapy, defining the low and high risk groups and predicting 
distant metastasis. These gene-expression techniques 
have also been used to predict response to radiotherapy 
with an accuracy as high as 82.4%.82 Similar results have 
been reported by Ghadimi and colleagues83 when the gene 
expression was evaluated on a small subset of patients from 
the German Rectal Cancer Trial (CAO/ARO/AIO-94). The 
authors studied the expression of 54 genes in 23 patients with 
locally advanced rectal cancer and demonstrated positive and 
negative predictive values of 78% and 86%, respectively, 
in detecting the probable responders to preoperative 
chemoradiotherapy.
Conclusion
The recent trend of events in management of rectal cancer 
indicates a multimodality approach. Although sphincter 
preservation gives a better quality of life, it should not be the 
aim at the cost of curative resection. Early rectal cancers are 
favorable tumors and specific subsets are amenable to local 
excision. The role of transanal endoscopic microsurgery is 
promising in this regard. With evolution of recent imaging 
modalities like TRUS, MRI, PET-CT scans, etc., the exact 
stage determination is possible, which is an important step 
in the work up of a patient with rectal cancer. Treatment of 
locally advanced disease has been the most explored area 
in the last decade. In brief, progression from postoperative 
RT to preoperative RT to preoperative CRT to improved 
chemotherapy techniques (drugs increasing effect of 
chemotherapy) in preoperative CRT to addition of adjuvant 
postoperative CT has best defined the changing trends in 
the treatment of rectal cancer with an aim to eradicate local 
recurrence and in the long run to increase survival. The 
concurrent concepts of short and long-course preoperative RT 
although still present, are giving way to neoadjuvant CRT. 
Although neoadjuvant CRT decreases local recurrence, it does 
not improve survival. All these advances have been made 
possible by better understanding of tumor biology especially 
various gene expression of rectal cancers. Predictive markers 
of cancer response to CRT are very much needed not only to 
decrease useless treatment but also to better select the right 
subset of patients. Lastly, efforts are on the way to assess 
the predictors of nonoperative management in early rectal 
tumors who have shown complete clinical and pathological 
response after preoperative CRT.Clinical and Experimental Gastroenterology 2009:2 58
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